RESUMO
INTRODUCTION: Smoking has been associated with increased incidence, severity of cutaneous lupus, and lupus activity. We looked at the association of both smoking and ethnicity with the individual damage items from the SLICC/ACR Damage Index. METHODS: Poisson regression was used to model the total SLICC/ACR Damage Index score against ever smoking. Cox regression was used to assess the relationship between time to individual damage items and ever smoking. Furthermore, we compared SLICC/ACR Damage Index items among African-American and Caucasian ever smokers. RESULTS: The study included 2629 patients, 52.6% Caucasian and 39.3% African-American. The prevalence of ever smokers was 35.8%. There was no significant difference in total SLICC/ACR Damage Index score between ever smokers and never smokers after adjustment for ethnicity, gender, age at diagnosis, and years of education. Ever smokers had more atherosclerotic cardiovascular damage and skin damage compared to non-smokers. Caucasian SLE patients who ever smoked were more likely to have muscle atrophy and atherosclerosis compared to Caucasian non-smokers. African-American patients who ever smoked were more likely to have skin damage compared to African-American non-smokers. African-Americans who smoked were more likely to have many more damage items (cataract, renal damage, pulmonary hypertension, cardiomyopathy, deforming or erosive arthritis, avascular necrosis, skin damage, and diabetes) compared to Caucasians who smoked. CONCLUSION: Our analysis proved the major effect of smoking on cardiovascular and cutaneous damage. Surprisingly, cardiovascular damage items had higher hazard ratios in Caucasian smokers than non-smokers while skin damage items hazard ratios were higher in African-American smokers compared to non-smokers.Key Points⢠This study is the largest cohort study to date evaluating the effect of smoking on the cumulative SLICC/ACR Damage Index and its individual damage items.⢠It is the only study that examined the effect of smoking on individual items of the SLICC/ACR Damage Index in terms of Caucasians vs. African-American ethnicity.⢠Our analysis proved the major effect of smoking on cardiovascular and cutaneous damage. Compared to non-smokers, Caucasian smokers had higher risk of cardiovascular damage while African-American smokers had more skin damage.⢠African-Americans who smoked were more likely to have many more damage items (cataract, renal damage, pulmonary hypertension, cardiomyopathy, deforming or erosive arthritis, avascular necrosis, skin damage, and diabetes) compared to Caucasians who smoked.
Assuntos
Artrite/etnologia , Negro ou Afro-Americano/estatística & dados numéricos , Doenças Cardiovasculares/etnologia , Fumar Cigarros/epidemiologia , Diabetes Mellitus/etnologia , Falência Renal Crônica/etnologia , Lúpus Eritematoso Sistêmico/etnologia , População Branca/estatística & dados numéricos , Adulto , Alopecia/epidemiologia , Alopecia/etnologia , Artrite/epidemiologia , Aterosclerose/epidemiologia , Aterosclerose/etnologia , Cardiomiopatias/epidemiologia , Cardiomiopatias/etnologia , Doenças Cardiovasculares/epidemiologia , Catarata/epidemiologia , Catarata/etnologia , Cicatriz/epidemiologia , Cicatriz/etnologia , Estudos de Coortes , Diabetes Mellitus/epidemiologia , Ex-Fumantes , Feminino , Humanos , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/etnologia , Falência Renal Crônica/epidemiologia , Estudos Longitudinais , Lúpus Eritematoso Cutâneo/epidemiologia , Lúpus Eritematoso Cutâneo/etnologia , Lúpus Eritematoso Sistêmico/epidemiologia , Nefrite Lúpica/epidemiologia , Nefrite Lúpica/etnologia , Masculino , Pessoa de Meia-Idade , Atrofia Muscular/epidemiologia , Atrofia Muscular/etnologia , não Fumantes , Osteonecrose/epidemiologia , Osteonecrose/etnologia , Modelos de Riscos Proporcionais , Fumantes , Tempo , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Patient-reported outcomes (PROs) are gaining an important role in the assessment of quality of care. There are currently limited data on the effect of payer type on PROs in total joint arthroplasty (TJA). This study compared both disease-specific and general health PROs among patients stratified according to their payer type. METHODS: Our institutional joint registry was queried for patients who underwent primary, elective, and unilateral hip and knee arthroplasty. Patients were divided according to their insurance type at the time of surgery into 3 groups: Medicaid, Medicare, or commercial. The outcomes assessed were the net changes in PROs as well as absolute scores at 6 months and 1 year. Six of the most commonly used PROs were assessed: Short Form-12 physical and mental components, Western Ontario and McMaster Universities Osteoarthritis Index, Single Assessment Numerical Evaluation, University of Californian Los Angeles activity level rating, and Oxford Hip Score. Analysis of variance and covariance were used. RESULTS: We evaluated 756 procedures (273 Medicaid, 270 Medicare, and 213 commercial insurance). Medicaid patients had significantly lower mean baseline scores across all PROs compared to either Medicare or commercial insurance patients. Medicaid patients were also more likely to be smokers, live alone, have lower educational level, African-American, and have nonprimary osteoarthritis as the indication for TJA. At 1-year follow-up, the net mean outcome gains were comparable among the 3 payer types (P > .05), but Medicaid patients continued to score lower while Medicare and commercial insurance patients continued to score higher (P < .01). When adjusting for all baseline differences among Medicaid patients, the negative effects of payer type resolved except for Oxford Hip Score which remained lower in the Medicaid group (P = .006). CONCLUSION: When using PROs to assess the value of care, the preoperative to postoperative changes are a better indicator of surgical success than comparing absolute values, especially in Medicaid patients. While TJA imparts similar net improvements to patients of all payer types, Medicaid coverage is a predictor of lower absolute outcome scores at any given time as result of increased baseline health burden (eg, depression, tobacco smoking, and poor overall well-being). Arthroplasty surgeons should be aware of these factors when counseling patients and seek optimization when necessary. The findings should be taken into account by stakeholders when constructing value-based payment models. Further research is needed to better understand the barriers leading to higher prevalence of increased health disparities among Medicaid beneficiaries and how to effectively address them.
Assuntos
Artroplastia de Quadril/economia , Artroplastia do Joelho/economia , Procedimentos Cirúrgicos Eletivos/economia , Osteoartrite do Quadril/cirurgia , Osteoartrite do Joelho/cirurgia , Osteonecrose/cirurgia , Medidas de Resultados Relatados pelo Paciente , Idoso , Artroplastia de Quadril/estatística & dados numéricos , Artroplastia do Joelho/estatística & dados numéricos , Procedimentos Cirúrgicos Eletivos/estatística & dados numéricos , Etnicidade , Feminino , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde , Humanos , Seguro Saúde , Masculino , Medicaid/economia , Medicare/economia , Pessoa de Meia-Idade , Osteoartrite do Quadril/etnologia , Osteoartrite do Joelho/etnologia , Osteonecrose/etnologia , Período Pós-Operatório , Setor Privado , Qualidade da Assistência à Saúde , Sistema de Registros , Índice de Gravidade de Doença , Inquéritos e Questionários , Estados UnidosRESUMO
OBJECTIVE: The aim of this population-based study is to examine the adverse events (AE) associated with longitudinal systemic glucocorticoid (GC) use among an ethnic Chinese systemic lupus erythematosus (SLE) cohort. METHODS: Our study subjects were patients with newly diagnosed SLE aged 18 and older who received at least 1 prescription of systemic GC between 2001 and 2012 from Taiwan's National Health Insurance Research Database (NHIRD). The earliest prescription date of systemic GC for each subject was defined as the index date. For each subject, we calculated the average prednisolone-equivalent dose and the medication possession ratio (MPR) of GC use every 90 days for each patient after the index date. Patients with a diagnosis of AE (defined by the International Classification of Diseases-9-Clinical Modification diagnosis code) during the followup were also identified from the NHIRD. Generalized estimating equations adjusted for propensity score were applied to examine the association between longitudinal GC use and risks of prespecified AE (musculoskeletal, gastrointestinal, ophthalmologic, infectious, cardiovascular, neuropsychiatric, metabolic, and dermatologic diseases). RESULTS: We identified 11,288 patients with SLE (mean followup: 6.28 yrs). Higher doses and higher MPR of GC were associated with increased risk of osteonecrosis [adjusted OR (aOR) 2.87-9.09]. Similar results were found regarding the risk of osteoporosis (aOR 1.71-3.67), bacterial infection (aOR 2.12-3.89), Cushingoid syndrome (aOR 6.51-62.03), and sleep disorder (aOR 1.42-3.59). CONCLUSION: To our knowledge, this is the first study to show that the dose and intensity of longitudinal use of GC were both associated with risk of AE among a nationwide Asian SLE cohort.
Assuntos
Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/etnologia , Adulto , Infecções Bacterianas/etnologia , Infecções Bacterianas/etiologia , Síndrome de Cushing/etnologia , Síndrome de Cushing/etiologia , Bases de Dados Factuais , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Glucocorticoides/administração & dosagem , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Programas Nacionais de Saúde , Osteonecrose/etnologia , Osteonecrose/etiologia , Osteoporose/etnologia , Osteoporose/etiologia , Índice de Gravidade de Doença , Transtornos do Sono-Vigília/etnologia , Transtornos do Sono-Vigília/etiologia , Taiwan/etnologia , Resultado do Tratamento , Adulto JovemRESUMO
PURPOSE: This study compared the relative incidence of treatment-related toxicities and the event-free and overall survival between Hispanic and non-Hispanic children undergoing therapy for acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute ALL Consortium protocol 05-001. PATIENTS AND METHODS: Secondary analysis of prospectively collected data from a phase III multicenter study in children and adolescents of 1-18 years with previously untreated ALL. RESULTS: Between 2005 and 2011, 794 eligible patients enrolled on DFCI 05-001, 730 of whom were included in this analysis (19% [N = 150] Hispanic, 73% [N = 580] non-Hispanic). Hispanic patients were more likely to be ≥10 years of age (32% vs. 24%, P = 0.045) at diagnosis. Toxicity analyses revealed that Hispanic patients had significantly lower cumulative incidence of bone fracture (P < 0.001) and osteonecrosis (ON; P = 0.047). In multivariable risk regression, the risk of ON was significantly lower in Hispanic patients ≥10 years (HR 0.23; P = 0.006). Hispanic patients had significantly lower 5-year event-free survival (EFS) (79.4%; 95% CI: 71.6-85.2) and overall survival (OS) (89.2%; 95% CI: 82.7-93.4) than non-Hispanic patients (EFS: 87.5%; 95% CI: 84.5-90.0, P = 0.004; OS: 92.7%; 95% CI: 90.2-94.6, P = 0.006). Exploratory analyses revealed differences between Hispanic and non-Hispanic patients in the frequency of common variants in genes related to toxicity or ALL outcome. CONCLUSION: Hispanic children treated for ALL on DFCI 05-001 had fewer bone-related toxicities and inferior survival than non-Hispanic patients. While disease biology is one explanatory variable for outcome disparities, these findings suggest that biologic and non-biologic mechanisms affecting drug delivery and exposure in this population may be important contributing factors as well.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Hispânico ou Latino , Osteonecrose , Leucemia-Linfoma Linfoblástico de Células Precursoras , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Criança , Pré-Escolar , Intervalo Livre de Doença , Feminino , Fraturas Ósseas/induzido quimicamente , Fraturas Ósseas/etnologia , Fraturas Ósseas/mortalidade , Humanos , Incidência , Lactente , Masculino , Osteonecrose/induzido quimicamente , Osteonecrose/etnologia , Osteonecrose/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/etnologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Taxa de SobrevidaRESUMO
PURPOSE: In Kienböck's disease, the wrist displays certain characteristic radiological parameters, which have been reported to differ among countries. In the present study, we aimed to identify specific radiological parameters of the unaffected wrists in patients with unilateral Kienböck's disease and to determine the extent of the association of each parameter with the disease in Korea. METHODS: This retrospective case-control study assessed the radiological parameters of patients with Kienböck's disease ( n = 53) and controls ( n = 53), who visited our institution between January 2000 and May 2013. Ulnar variance (UV), radial inclination, lunate fossa inclination, lunate diameter, lunate height, lunate tilting angle (LTA), lunate covering index (LCI), and Ståhl index (SI) were measured and analyzed using a binary logistic regression model. RESULTS: We observed that wrists with a high LTA and LCI, and low UV and SI had a tendency to develop Kienböck's disease. CONCLUSION: In the Korean population, a high LTA and LCI, and low UV and SI of the unaffected wrists on plain radiography might be associated with Kienböck's disease. The radiographic characteristics of the unaffected wrists can differ between patients with unilateral Kienböck's disease and normal individuals.
Assuntos
Povo Asiático , Osso Semilunar/diagnóstico por imagem , Osteonecrose/diagnóstico por imagem , Osteonecrose/etnologia , Articulação do Punho/diagnóstico por imagem , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radiografia , República da Coreia , Estudos Retrospectivos , Adulto JovemRESUMO
Introdução: Os bifosfonatos são análogos dos pirofosfatos endógenos e possuem alta afinidade pelos tecidos mineralizados, atuando em sítios de grande formação e reabsorção óssea, sendo utilizados no tratamento da osteoporose, osteogênese imperfeita, displasia fibrosa, doença de Paget, mieloma múltiplo e nas metástases ósseas das complicações de vários tipos de neoplasias malignas. Contudo, numerosas complicações de seu uso vêm sendo descritas, destacando-se o aparecimento de osteonecrose nos ossos gnáticos.Objetivo: Alertar o cirurgião-dentista sobre os possíveis efeitos colaterais dessa classe de drogas sobre o tecido ósseo, os quais podem se assemelhar à outras patologias, como a osteorradionecrose e osteomielites. Verificou-se que a osteonecrose por bifosfonatos é mais comum em pacientes com mieloma múltiplo e câncer de mama, embora também tenha sido relatada em pacientes sob tratamento para osteoporose. Com relação à etiologia, sugere-se uma relação com exodontias e alterações periodontais, embora casos aparentemente espontâneos tenham sido relatados. A despeito da severidade da patologia, não existem protocolos bem estabelecidos de tratamento, variando de conservadores, utilizando a antibioticoterapia e bochechos com clorexidina 0,12%, à radicais, como a mandibulectomia e maxilectomia. Tratamentos alternativos também podem ser realizados, utilizando-se o plasma rico em plaquetas associado às ressecções. Diante dos efeitos dos bifosfonatos aos ossos gnáticos, deve-se dar enfâse à prevenção realizando exames clínicos e radiográficos, a fim de detectar possíveis infecções dentais e realizar os procedimentos convenientes como extrações dentárias, tratamentos endodônticos e periodontais, além de remoção de torus mandibulares ou maxilares, uma das áreas anatômicas mais acometidas.Conclusão: A instituição de protocolos prévios odontológicos a terapia dos bifosfonatos deveria ser uma rotina no início do tratamento médico, promovendo assim à prevenção da osteonecrose.